A 71-year-old White man with a history of hip fracture is diagnosed with osteoporosis. Which medication or class is considered first-line therapy for men with osteoporosis?

Choice A reason: Bazedoxifene is a selective estrogen receptor modulator (SERM) primarily used in postmenopausal women for osteoporosis prevention and treatment. It is not approved or recommended as first-line therapy for men with osteoporosis due to its estrogen-related mechanism of action. Choice B reason: Risedronate is a bisphosphonate and is effective in treating osteoporosis. However, it is a specific agent within the bisphosphonate class. While it may be used, the broader class of bisphosphonates is considered first-line, allowing for individualized selection among agents like alendronate, risedronate, or zoledronic acid. Choice C reason: Bisphosphonates are the first-line therapy for osteoporosis in men. They work by inhibiting osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk. Their efficacy, safety profile, and long-term data support their use as the standard initial treatment. Choice D reason: Denosumab is a monoclonal antibody that inhibits RANKL, reducing bone resorption. It is effective in treating osteoporosis and may be used in men, especially those who cannot tolerate bisphosphonates or have contraindications. However, it is considered second-line or alternative therapy, not first-line.